John Cecil, MD
Pediatrics · Paducah, KYNPI 1821168154
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,441 of the $12,559 with a category attached, or 75.2%. 31 manufacturers reported payments, led by Supernus Pharmaceuticals, Inc. at 35.8% of the total. Reporting peaked in 2019 at $4,327 and has fallen 72.5% since, to $1,190 in 2025. Among pediatrics clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 653 payments — averaging $19.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$4K
- AbbVie$2K
- Corium, LLC$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$713
- Takeda Pharmaceuticals U.S.A., Inc.$672
- plus $2K from 25 others
What the payments were for
- Speaking & faculty fees$2,00016%
- Travel & lodging$1,0448%
- Food & beverage$9,44175%
- Education$741%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 82 | $4,492 |
| AbbVie(2 entities) | 162 | $1,999 |
| Corium, LLC | 108 | $1,377 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 95 | $1,125 |
| Otsuka America Pharmaceutical, Inc. | 33 | $713 |
| Takeda Pharmaceuticals U.S.A., Inc. | 46 | $672 |
| Shire North American Group Inc | 29 | $371 |
| Axsome Therapeutics, Inc. | 12 | $265 |
| Ironshore Pharmaceuticals Inc. | 12 | $211 |
| Sunovion Pharmaceuticals Inc. | 13 | $203 |
| Novo Nordisk | 10 | $170 |
| Tris Pharma Inc | 4 | $142 |
| Lilly USA, LLC | 10 | $135 |
| Alkermes, Inc. | 5 | $101 |
| Johnson & Johnson(2 entities) | 4 | $91 |
| Collegium Pharmaceutical, Inc. | 4 | $68 |
| Lundbeck LLC | 3 | $65 |
| Pfizer | 3 | $55 |
| Neos Therapeutics, LP | 2 | $39 |
| Genentech USA, Inc. | 3 | $37 |
| OWP Pharmaceuticals, Inc. | 2 | $33 |
| Bayer | 1 | $29 |
| Zyla Life Sciences, Inc. | 2 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Amgen | 1 | $19 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| GSK | 1 | $18 |
| Exact Sciences | 1 | $17 |
| Antares Pharma, Inc. | 1 | $15 |
| Adlon Therapeutics L.p. | 1 | $11 |
How this compares
$12,559 in reported general payments places this provider in the 95th percentile of 777 pediatrics providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 232 | $69,936 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 177 | $36,978 |
| CaplytaLumateperone Tosylate | 15 | $24,638 |
| VraylarCariprazine Hcl | 14 | $19,628 |
| EliquisApixaban | 21 | $15,447 |
| MresviaRsv Vaccine, Pref, Mrna/Pf | 48 | $14,122 |
| VyvanseLisdexamfetamine Dimesylate | 33 | $12,901 |
| Lisdexamfetamine Dimesylate | 22 | $4,688 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 90 | $3,179 |
| Methylphenidate ErMethylphenidate Hcl | 34 | $3,058 |
| Vilazodone Hcl | 29 | $1,525 |
| SynthroidLevothyroxine Sodium | 17 | $1,353 |
| Boostrix TdapDiphth,pertuss(Acell),tet Vac | 21 | $1,339 |
| Atorvastatin Calcium | 155 | $1,270 |
| Gabapentin | 127 | $1,032 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerAbrysvo, Eliquis | $55 | $85,383253 claims |
| GSKShingrix | $18 | $36,978177 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,125 | $24,63815 claims |
| AbbVieVraylar, Synthroid | $1,999 | $20,98131 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $672 | $12,90133 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 777 pediatrics providers in Kentucky.
Other pediatrics in Paducah
- Caitlyn CecilPaducah$3K
- Jessie MeiserPaducah$3K
- John RoachPaducah$3K
- Jeffrey MuddPaducah$2K
- Sirish PalleHyden$89K
- Christian BerkhahnLouisville$85K
- Maurice AllgeierLouisville$38K
- Stanley BlockBardstown$34K
- Michael SimonNicholasville$32K
- Patricia PurcellLouisville$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.